MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments
about
Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) studyDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryVaginal drug distribution modelingMulticompartmental pharmacokinetic model of tenofovir delivery by a vaginal gelQuantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopyDaily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with menCorrelation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 studyMucosal effects of tenofovir 1% gelIntravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.Vaginal deployment and tenofovir delivery by microbicide gelsDisclosure of pharmacokinetic drug results to understand nonadherenceHow common and frequent is heterosexual anal intercourse among South Africans? A systematic review and meta-analysis.Biomedical prevention: state of the science.Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couplesTenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.Topical microbicides and HIV prevention in the female genital tractA multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.Pharmacokinetics of antiretrovirals in mucosal tissueGenital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women.Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 PreventionAn intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates.A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel
P2860
Q26777022-5BF1DBB5-F57D-4F30-B820-C3F0A37AE5D7Q27300707-CF1BF476-D0EA-45D7-8EEE-C16C5D862828Q28081272-CC8C0932-5621-463E-9D9B-7D61646430A1Q28088306-084D80E2-872B-4B09-92B3-E983821B9759Q28533251-2829FE0D-DC6A-4FC1-9578-D9954D5E232EQ28538105-4A8F282B-D6B9-493D-9640-6FFBB0EE4340Q28540969-5F2C968A-B88D-4A7F-9CF0-75918CDE2346Q28544439-2CC69DE8-BDED-4939-A452-FC7884BE11FAQ28545969-0298DBAA-AAA2-4ABA-BEBD-3343572EC5E7Q30447923-DE899929-82E8-46F3-98E1-E349FF9BAF7FQ30647900-3CD54E8C-48DF-4B8F-8304-63C7AD4B12D6Q30674432-3A3BF606-BBFF-4D68-92C0-DE61375AF77CQ30854994-0C4E5A5D-9BFE-4310-8446-6ADC8CCA158FQ33765795-BAF840E5-CDD2-46BE-842E-5C3CDFC134F9Q33798045-0CE3CBBB-A6C3-4971-8C8C-19E0A85AA63CQ33821090-809D14E4-6FDD-4E75-A0BB-A224900ACD04Q33825769-9FDA9089-9E5A-49FB-AD93-993F3C9C7C41Q33888718-9ADF5C23-EC29-4F34-B1B6-E635171FC4FAQ34021932-493230D6-19A6-4D3A-B3F8-D540C205C0E8Q34034418-AE5635EE-C0E0-4BDE-98C2-75BD94C1F336Q34057568-77A67EDD-816E-4946-8DE8-7389FEBBB72FQ34086820-BAA7B239-AF40-4190-B0EE-C18FA2E86D57Q34414539-78C7D6A7-85ED-468F-B8CD-D2B8D30A075DQ34658079-0055E47D-4844-406B-86B7-3BD2D8001A89Q35033732-23D9C8F3-EFAF-4DA2-B38C-44EB1514FAD8Q35102123-69D1E9D0-9CA0-4FA0-A2D4-95F5A2904976Q35571216-4921C593-8281-4860-BCE0-030133731C04Q35746114-AFB27890-11FC-4028-96E7-592FF893F9BEQ35838594-CE721631-92A1-4372-BE38-A6AABD57D8E8Q35861437-0BECE5A4-97EA-4565-884C-6233035794E6Q36068904-813C5705-3D9D-4701-9F3F-8A6E834744E6Q36106256-4C780F1A-A0C4-490A-85C1-B06172758DC5Q36143276-75A771AB-5A04-47A1-8E52-6F8F23A1B55FQ36173759-8459E992-4CF5-4ADD-AB95-9DBF0429000FQ36294765-1405A2EF-A7B2-4476-B3BB-FEBF35363D91Q36294792-95BCDF02-95AD-46DB-9D1E-A68127199287Q36306926-1B5C869B-6FC7-4810-AD36-9415CC47960BQ36406923-1DDEC3AC-7508-418E-BC9D-2C4151DFA18DQ36440225-C5950863-E39A-40C7-9C7D-D25AE98B5187Q36446138-D1ACEF61-DFA5-4204-9388-3ECF7E2CF4A0
P2860
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
MTN-001: randomized pharmacoki ...... tissue and other compartments
@ast
MTN-001: randomized pharmacoki ...... tissue and other compartments
@en
MTN-001: randomized pharmacoki ...... tissue and other compartments
@nl
type
label
MTN-001: randomized pharmacoki ...... tissue and other compartments
@ast
MTN-001: randomized pharmacoki ...... tissue and other compartments
@en
MTN-001: randomized pharmacoki ...... tissue and other compartments
@nl
prefLabel
MTN-001: randomized pharmacoki ...... tissue and other compartments
@ast
MTN-001: randomized pharmacoki ...... tissue and other compartments
@en
MTN-001: randomized pharmacoki ...... tissue and other compartments
@nl
P2093
P2860
P3181
P1433
P1476
MTN-001: randomized pharmacoki ...... tissue and other compartments
@en
P2093
Alexandra M Minnis
Barbra A Richardson
Beatrice A Chen
Clemensia Nakabiito
Craig Hoesley
Craig W Hendrix
Jessica Justman
Kailazarid Gomez
Karen Patterson
Lydia Soto-Torres
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0055013
P407
P577
2013-01-01T00:00:00Z